# **ModernGraham Valuation**

## **Company Name:**

Company Ticker DVA Date of Analysis Davita Inc



## Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

3/13/2019

Defensive Investor; must pass 6 out of the following 7 tests.

1.	Adequate Size of the Enterprise	Market Cap > \$2Bil	\$8,952,319,873	Pass
2.	Sufficiently Strong Financial Condition	Current Ratio > 2	1.72	Fail
3.	Earnings Stability	Positive EPS for 10 years prior		Pass
4.	Dividend Record	Dividend Payments for 10 years prior		Fail
5.	Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	17.39%	Fail
6.	Moderate PEmg Ratio	PEmg < 20	18.25	Pass
7.	Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	2.29	Pass
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.				

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	1.72 Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	2.31 Fail
3. Earnings Stability	Positive EPS for 5 years prior	Pass
4. Dividend Record	Currently Pays Dividend	Fail
5. Earnings Growth	EPSmg greater than 5 years ago	Pass
	Score	

#### Suitability

Defensi	ive	No
Enterpr	ising	No

#### Stage 2: Determination of Intrinsic Value

EPSmg		\$2.94
MG Growth Estimate		3.21%
MG Value		\$43.95
MG Value based on 3% Growth		\$42.70
MG Value based on 0% Growth		\$25.03
Market Implied Growth Rate		4.87%
Current Price		\$53.74
% of Intrinsic Value		122.29%
Opinion	Overvalued	
MG Grade	D	
	MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price % of Intrinsic Value Opinion	MG Growth Estimate MG Value MG Value based on 3% Growth MG Value based on 0% Growth Market Implied Growth Rate Current Price % of Intrinsic Value Opinion Overvalued

### Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	-\$40.73
Graham Number	\$45.04
PEmg	18.25
Current Ratio	1.72
PB Ratio	2.29
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0
Glowin	0

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate		Next Fiscal Year Estimate	\$2.94
Dec2018	\$0.92	Dec2018	\$2.48
Dec2017	\$3.47	Dec2017	\$3.19
Dec2016	\$4.29	Dec2016	\$3.01
Dec2015	\$1.25	Dec2015	\$2.43
Dec2014	\$3.33	Dec2014	\$2.91
Dec2013	\$2.95	Dec2013	\$2.61
Dec2012	\$2.74	Dec2012	\$2.36
Dec2011	\$2.48	Dec2011	\$2.11
Dec2010	\$1.97	Dec2010	\$1.88
Dec2009	\$2.03	Dec2009	\$1.76
Dec2008	\$1.77	Dec2008	\$1.55
Dec2007	\$1.78	Dec2007	\$1.37
Dec2006	\$1.37	Dec2006	\$1.11
Dec2005	\$1.10	Dec2005	\$0.92
Dec2004	\$1.08	Dec2004	\$0.76
Dec2003	\$0.78	Dec2003	\$0.48
Dec2002	\$0.61	Balance Sheet Information	12/1/2018
Dec2001	\$0.48	Total Current Assets	\$8,424,159,000
Dec2000	\$0.05	Total Current Liabilities	\$4,891,161,000
Dec1999	-\$0.60	Long-Term Debt	\$8,172,847,000
		Total Assets	\$19,110,252,000
		Intangible Assets	\$6,960,806,000
		Total Liabilities	\$15,201,854,000
		Shares Outstanding (Diluted Average)	166,413,000





#### Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

#### **Recommended Reading:**

Other ModernGraham posts about the company	DaVita Inc Valuation – June 2018 \$DVA Davita Inc Valuation – February 2017 \$DVA DaVita HealthCare Partners Inc Valuation – November 2015 Update \$DVA 30 Companies in the Spotlight This Week – 11/15/14 DaVita Healthcare Partners Inc. Annual Valuation – 2014 \$DVA	
Other ModernGraham posts about related companies	Danaher Corp Valuation – March 2019 #DHR Agilent Technologies Inc Valuation – March 2019 #A ResMed Inc Valuation – March 2019 #RMD Cooper Companies Inc Valuation – March 2019 #COO Edwards Lifesciences Corp Valuation – March 2019 \$EW Boston Scientific Corporation Valuation – March 2019 \$ESX Baxter International Inc Valuation – March 2019 \$BAX	

Centene Corp Valuation – March 2019 \$CNC Abbott Laboratories Valuation – February 2019 \$ABT Becton Dickinson and Co Valuation – February 2019 \$BDX